Skip to main content

Changes of migraine aura with advancing age of patients

A Correction to this article was published on 14 August 2023

This article has been updated



Given the similar presentation of migraine aura and acute ischemic stroke, advancing patient age might change the characteristics of migraine with aura (MA) and be clinically important. Clinical data, however, are limited. Experimental studies indicate a decrease in the magnitude of cortical spreading depression (CSD), the pathophysiological correlate of migraine aura, with advancing age. Our study aimed to assess the influence of age on the clinical features of MA.


Three hundred and forty-three patients were interviewed using a structured questionnaire. The questions covered the headache characteristics and symptom types including the characteristics of the C-criterion, as defined by the International Classification of Headache Disorders 3rd Edition. The association of age with MA characteristics was assessed.


The median age was 29 (IQR 28–52) and 235 of the 343 patients were women (69%). Individual symptoms of the C-criterion such as gradual aura spreading over longer than 5 min (P < 0.001), two or more aura symptoms occurring in succession (P = 0.005), duration of at least one MA symptom for longer than 60 min (P = 0.004), and associated headache (P = 0.01) were more frequent in younger patients. The number of symptoms (P = 0.003) including the C-characteristics decreased with increasing age (P < 0.027). Patients with sensory (P < 0.001), motor (P = 0.04) and speech disturbance (P = 0.02) were younger, and older patients with headache had less photophobia (P = 0.04) and phonophobia (P = 0.03). Sensitivity analyses yielded similar results.


The frequency of typical characteristics of migraine aura and migraine headache including photophobia and phonophobia decreases with advancing patient age. This might have potentially difficult implications for the diagnosis of MA in the elderly.

Peer Review reports


Migraine with aura (MA) symptoms are defined by the current diagnostic criteria [1] and include, for the aura, slow development, duration of 5–60 min, complete reversibility, positive irritative focal neurological symptoms, and accompaniment by headache within one hour of symptom onset. However, clinical observations showed that some patients with migraine aura do not have headache [2,3,4] and that an individual aura symptom might last longer than the 60 min allowed by the current criteria [5, 6]. The canonical cortical spreading depression (CSD) represents a slowly occurring and spreading depolarization across the cortex that is assumed to be the pathophysiological explanation for migraine aura [7]. Although CSD fits many of the clinical features of MA, it does not explain the full picture, especially not the clinical variability.

Experimental studies in rats showed that older age correlated negatively with CSD propagation [8]. However, there are limited clinical data on the influence of age on MA symptoms in humans. Aiba et al. [2] report a biphasic age-distribution of MA without headache. Donnet et al. [9] found that new onset MA in patients over 50 was not associated with headache or was accompanied more often by headache with non-migrainous features, and Hansen et al. describe less nausea with advancing age [10]. By contrast, Viana et al. did not find age to be a significant factor associated with prolonged aura in univariate analysis [11]. There is limited information on the influence of age on the individual symptoms of migraine aura.

The aim of this study was to assess the impact of age on MA symptoms. We hypothesized that the number of typical migraine features in MA decreases with advancing age.


This monocentric cross-sectional study was approved by the local ethics committee (2018–02258). The methods were previously reported [12]. In short, patients with MA diagnosed according to the International Classification of Headache Disorders 3rd edition (ICHD-3) [1] were interviewed using a structured questionnaire. The questions covered the type of symptoms, temporal aspects such as symptom onset and duration, the succession of symptoms, headache characteristics of a usual MA attack, as well as co-morbidities. Inclusion criteria for the study were verified diagnosis of MA, age more than 18 years and last migraine attack less than 12 months prior to the interview.

Statistical analyses

Frequencies are presented as counts, crude odds ratios and confidence intervals, calculated using Wilson’s method. Continuous variables are presented as medians with interquartile range (IQR). For univariate comparisons of categorical variables \({x}^{2}\) or Fisher’s exact were used, as appropriate. For comparisons of continuous variables, the Mann–Whitney or Kruskal–Wallis test was used, as appropriate. For multiple comparisons, Bonferroni correction has been performed. A P value of < 0.05 was considered significant. Further, the association between the number of symptoms and age was calculated. Only visual, sensory, motor and speech symptoms were considered, given their well-defined cortical distribution. Given that the influence of acute or preventative therapy on headache was not assessed, headache frequency, intensity and duration were not included in the analysis. Specifically, we looked at the temporal succession of headache and aura, headache location, headache character, aggravation of headache by routine physical activity, nausea, photo- and phonophobia.

Sensitivity analyses

As sensitivity analyses univariate comparisons between patients younger and older than 60 years were performed. Furthermore, the interaction between C-characteristics, age per 10 years and sex was assessed using multivariable logistic regression. To assess the goodness of fit of the prediction model, the Pearson \({x}^{2}\) test was performed. Additionally, we performed post-hoc power analyses for all outcomes with a significance level of alpha of 0.05. For outcomes consisting of comparisons between two groups, we used the mean differences, for three or more groups the one-way ANOVA test. A power of at least 0.8 was considered sufficient. The statistical analyses were performed in STATA/MP 16.0, StataCorp LLC.


Three hundred and forty-three patients were interviewed. The median age was 29 (IQR 28–52) and 235 of the 343 patients were women (69%). The interviews took place after a median of 28 days (IQR 7–118) after the last MA attack. For an overview of the association of each C-characteristic and age see Fig. 1.

Fig. 1
figure 1

Association between each C-characteristic and age


C1-characteristic of the C-criterion – at least one symptom spreads gradually over 5 min

The C1 characteristic was fulfilled in 245/343 (71%). Those with fulfilled C1-characterstic were younger (median age 36 years [IQR 28–50] vs 44 [34–58], P < 0.001). In 205/343 (60%) patients at least one symptom spread either suddenly or over less than 5 min and in 15 (4%) over longer than 60 min. Although those with at least one slow-spreading symptom (i.e. > 60 min) were younger, the difference was not significant (34 years [IQR 26–51] vs 39 [29–53], P = 0.23). Patients with at least one symptom that spread < 5 min had a similar age compared with those with symptom onset of > 5 min (39 years [30–52] vs 38 [27–53], P = 0.73).

C2-characteristic of the C-criterion—two or more aura symptoms occur in succession

The C2-characteristic of the C-criterion was fulfilled in 201/343 (59%). Those with fulfilled C2-characteristic were younger (median age 36 years [IQR 27–59] vs 41 [IQR 31–56], P = 0.005). Looking only at patients with at least two symptoms (211/343, 61.5%), the difference in the median age of those with and without fulfilled C2-characteristic was not significant (36 years [27–50] vs 33 [28–45], P = 0.73).

C3-characteristic of the C-criterion – each individual aura symptom lasts 5–60 min

The C3-characteristic of the C-criterion was fulfilled in 211/343 (62%). Those with fulfilled C3-characteristic were older (median age 40 years [IQR 29–57] vs 36 [28–48], P = 0.03).

One hundred four of 343 (30%) had at least one symptom that lasted longer than 60 min and 17 (5%) less than 5 min. Patients with symptoms lasting > 60 min were younger compared to those with symptoms lasting < 60 min (35 years [27–47] vs 40 [30–56], P = 0.004).

C4-characteristic of the C-criterion – at least one symptom is unilateral

The C4-characteristic was fulfilled in 327/343 (95%). There was no difference in median age between those with and without fulfilled C4-characteristic (38 years [IQR 29–52] vs 43[34–59], P = 0.36).

C5-characteristic of the C-criterion – at least one aura symptom is positive

The C5-characteristic was fulfilled in 323/343 (94%). There was no difference in median age between those with and without fulfilled C4-characteristic (median age 39 years [IQR 29–52] vs 35 [27–54], P = 0.82).

C6-characteristic of the C-criterion – the aura is accompanied, or followed within 60 min by headache.

The C6-characteristic was fulfilled in 315/343 (92%). Patients with headache were significantly younger (median age 38 years [IQR 29–51] vs 50 [33–65], P = 0.01). Looking at the headache characteristics, patients with photophobia (38 years [IQR 28–51]) were younger than those without (40 years [31–61], P = 0.04), as were those with phonophobia (37 years [IQR 28–51] vs 40 [31–57], P = 0.03). Other headache characteristics did not have an association with age (Table 1).

Table 1 Association of headache characteristics and age

Number of fulfilled C-characteristics

There were 39 patients (11% of 343) with three, 94 (27%) with four, 131 (38%) with five and 79 (23%) with six fulfilled C-characteristics. The median age of patients who had fulfilled three C-characteristics was 49 [IQR 35–57], older than patients with four (39 [31–52]), five (37 [27–48]) and six fulfilled C-characteristics (36 [27–55]). The four groups differed significantly from each other (PBonferroni = 0.027, Fig. 2). In post-hoc analysis, there was a significant difference between the subgroups with three and four (P = 0.03), three and five (P = 0.001) and three and six characteristics (P = 0.009), but no difference between those with four and five (P = 0.13), four and six (P = 0.24) and five and six C-characteristics (P = 0.9).

Fig. 2
figure 2

Association between number of fulfilled C-characteristics and age

Number of symptoms

There were 134 patients (39%) with one, 87 (25%) with two, 84 (24%) with three and 38 (11%) with four symptoms. Patients with one (median age 42 years [IQR 31–56]) and two symptoms (median age 40 years [31–53]) were older than those with three (median age 33 years [26–48]) and four symptoms (median age 34 years [26–45]). The four groups differed significantly from each other (PBonferroni = 0.003, Fig. 3). When comparing the subgroups for post-hoc analysis, there was a significant difference in age between patients with one and three symptoms (P = 0.0007), one and four (P = 0.007) and two and three symptoms (P = 0.02) but no difference between those with two and four (P = 0.07) and three and four symptoms (P = 0.89).

Fig. 3
figure 3

Association between number of symptoms and age

Type of symptoms

Patients with visual symptoms (n = 326, 95%) were older (median age 39 years [IQR 29–52]) than those without (n = 17, 5%) who were 35 years old in median [IQR 31–52], the difference not reaching significance (P = 0.73). Patients with sensory disturbance (n = 175, 51%) were significantly younger compared to those without (n = 166, 49%), i.e. median age of 34 years [IQR 27–48] vs 42 [32–57] (P < 0.001). Patients with paresis (n = 50, 15%) were also significantly younger (median age 34 years, [IQR 26–47]) compared to those without paresis (39 years [IQR 29–54]; P = 0.04) as were patients with speech disturbance (n = 160, 47%, median age 35 years [IQR 27–51]) compared to patients without (n = 183, 53%, median age 41 years [IQR 31–53], P = 0.02).

Of the patients without visual symptoms (n = 17), all (100%) had sensory, three (18%) had motor, and 7 (41%) had speech disturbance.

Of patients with paresis, 6/50 [12%] had bilateral paresis and there was no difference in age compared to those with unilateral paresis (median age 38 years [IQR 31–47] vs 34 [26–46], P = 0.42). Similarly, the age of the 22/50 (44%) patients with wandering motor symptoms was similar to those without (median 32 years [IQR 24–42] vs 36 [28–50], P = 0.17). The median age of patients with paresis lasting less than five minutes (n = 3/50 [6%], median age 33 years [IQR 23–50]) was similar to those with paresis lasting 5–60 min (n = 22/50 [44%], median age 33 years [IQR 25–47]) and 60 min to 24 h (17/50 [34%], median age 36 years [IQR 29–45]). However, patients with paresis lasting longer than 24 h were non-significantly younger than those without (n = 5/50 [10%], median age 26 years [IQR 26–31] vs 35 [30–48], P = 0.14). Only four patients (8% of 50) with paresis were older than 60 years.

Sensitivity analyses

The differences in C-characteristics were confirmed in our sensitivity analysis comparing people younger to older than 60 years old (Table 2), even after adjustment for sex (Tables 2 and 3).

Table 2 C-characteristics stratified by age
Table 3 Multivariable logistic regression for the C-characteristics and age (per 10 years) adjusted for sex

Looking at the differences in headache characteristics between patients younger and older than 60 years (Table 4), the significances for photophobia and phonophobia remained. However, a higher proportion of younger patients reported pulsating headache (45% vs 25%, P = 0.01) and aggravation by routine physical activity (77% vs 56%, P = 0.002). There was no difference for nausea (66% vs 54%, P = 0.09).

Table 4 Characteristics of headache stratified by age

With regard to the analyzed outcomes, the post-hoc analyses showed power levels of 1 for all C-characteristics, 0.95 for number of C-characteristics and 0.96 for number of symptoms (Supplemental Tables S1, S2 and S3).

The goodness of fit analyses with one degree of freedom showed P values higher than the predefined significance level of 0.05 and therefore the adjustment model for the logistic regression could not be rejected (Supplemental Table S4).


We analyzed the influence of age on the MA characteristics. The main findings of our study are: a) patients with gradually spreading symptoms over 5 min, symptoms occurring in succession, and symptoms lasting longer than 60 min were younger, b) patients with a higher number of aura symptoms were younger, c) patients with lack of headache were older and the headache, when present, was less often accompanied by photo- and phonophobia with advancing age, and d) patients with sensory symptoms, paresis or speech disturbance were younger.

The gradual onset of symptoms and symptoms occurring in succession are thought to be clinical expressions of the canonical CSD [1]. In this context, our results in a large group of patients fit the experimental findings in animals of a negative impact of older age on CSD propagation [8]. Similarly, the longer duration of aura symptoms in younger patients may correspond to a higher susceptibility to, or a longer duration of, CSD. It is plausible that the lower number of symptoms reported by older patients might reflect a smaller area of the cortex affected by CSD.

The association of older age with a lack of headache has been reported in previous studies [3, 4, 9, 13]. However, the precise reason for this association is not yet fully understood. The less intense CSD with advancing age might, at least in part, explain this finding. However, it is still debated which role CSD plays in the generation of migraine headache in patients with MA [7]. Curiously, with advancing age, less photo- and phonophobia were reported by those who did have headache with their aura, with patients younger than 60 years having more often pulsating headache and aggravation by routine physical activity. In our study, there was no significant difference in the prevalence of nausea based on age. However, it is worth noting that a non-significantly higher proportion of patients younger than 60 years experienced nausea with their episodes, in-line with previous reports [9, 10].

Overall, with advancing age, the MA tends to exhibit fewer typical features, and this has significant clinical implications. Considering that older patients are more prone to having vascular risk factors, there is a risk of misdiagnosing a migraine aura as an ischemic event, particularly if it occurs for the first time. The consequence may be unnecessary ancillary examinations and secondary prevention treatments. Conversely, an actual ischemic event might present with migraine-like symptoms, making it challenging or even impossible to differentiate between the two without further ancillary investigations [14,15,16,17].

In our study, we observed that patients with visual symptoms tended to be older. Therefore, even with advancing age, their presence should argue in favor of a migraine aura diagnosis. As previously discussed by Russel & Olesen, aura with sensory, motor and/or speech symptoms without visual symptoms should prompt suspicion of alternative etiologies [13]. Nevertheless, younger patients reported non-visual symptoms more frequently, which might make them less useful in the clinical differential diagnosis of MA in general. This is of particular importance given that younger patients are more likely to present with migraine-like symptoms during an ischemic stroke as well [18].

In our study, we included patients who met the ICHD-3 criteria for definite MA. Given the tendency of MA to become less typical for migraine aura with advancing age, it is possible that some cases of MA in older patients might have been overlooked.

Our study has limitations. First, we did not assess the intra-individual variability of the MA attacks. Second, the interview took place after a median of 28 days after the last attack with a large interquartile range (7–118), making our results susceptible to recall bias. However, patients with MA experience many attacks during their lifetime, which might reduce this problem. We did not assess whether the patients took treatment for their headache and therefore, we did not analyze the headache intensity and duration. Furthermore, we did not assess the use of migraine preventive medication, which could potentially influence the presentation and characteristics of MA. Also, we did not assess the socio-economic status, which may have an influence on the diagnosis and symptoms of MA [19, 20]. Lastly, the study design was cross-sectional, not allowing firm conclusions and further longitudinal studies are needed. The strengths are the large number of patients included and the assessment of symptoms using a personal interview and a structured questionnaire.

In conclusion, with advancing age, the characteristics of MA have fewer migraine-like features and the headache, when present, is accompanied by less migrainous features such as photo- and phonophobia. Our findings highlight the difficulties and challenges in the clinical diagnosis of MA with advancing age.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Change history



Migraine with aura


Cortical spreading depression


International Classification of Headache Disorders 3rd Edition


  1. (2018) Headache Classification Committee of the International Headache Society [IHS]. The international classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. PMID: 29368949

  2. Aiba S, Tatsumoto M, Saisu A et al (2010) Prevalence of typical migraine aura without headache in Japanese ophthalmology clinics. Cephalalgia 30(8):962–967

    Article  PubMed  Google Scholar 

  3. Amos JF, Fleming JB (2000) Clinical description and review of migraine aura without headache. Optometry 71:372–380

    CAS  PubMed  Google Scholar 

  4. Cologno D, Torelli P, Manzoni GC (1998) Migraine with aura: a review of 81 patients at 10–20 years’ follow-up. Cephalalgia 18(10):690–6

    Article  CAS  PubMed  Google Scholar 

  5. Viana M, Afridi S (2018) Migraine with prolonged aura: phenotype and treatment. Naunyn Schmiedebergs Arch Pharmacol 391(1):1–7

    Article  CAS  PubMed  Google Scholar 

  6. Viana M, Sances G, Linde M et al (2018) Prolonged migraine aura: new insights from a prospective diary-aided study. J Headache Pain 19(1):77

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bolay H, Vuralli D, Goadsby PJ (2019) Aura and Head pain: relationship and gaps in the translational models. J Headache Pain 20(1):94

    Article  PubMed  PubMed Central  Google Scholar 

  8. Guedes RCA, Abadie-Guedes R (2019) Brain aging and electrophysiological signaling: revisiting the spreading depression model. Front Aging Neurosci 11:136

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Donnet A, Daniel C, Milandre L, Berbis J, Auquier P (2012) Migraine with aura in patients over 50 years of age: the Marseille’s registry. J Neurol 259(9):1868–73

    Article  PubMed  Google Scholar 

  10. Hansen JM, Goadsby PJ, Charles AC (2016) Variability of clinical features in attacks of migraine with aura. Cephalalgia 36(3):216–24

    Article  PubMed  Google Scholar 

  11. Viana M, Linde M, Sances G et al (2016) Migraine aura symptoms: duration, succession and temporal relationship to headache. Cephalalgia 36(5):413–21

    Article  PubMed  Google Scholar 

  12. Scutelnic A, Kreis LA, Beyeler M et al (2022) Migraine aura-like symptoms at onset of stroke and stroke-like symptoms in migraine with aura. Front Neurol 13:1004058

    Article  PubMed  PubMed Central  Google Scholar 

  13. Russell MB, Olesen J (1996) A nosographic analysis of the migraine aura in a general population. Brain 119(Pt 2):355–61

    Article  PubMed  Google Scholar 

  14. Coutts SB, Moreau F, Asdaghi N, Diagnosis of Uncertain-Origin Benign Transient Neurological Symptoms (DOUBT) Study Group et al (2019) Rate and prognosis of brain ischemia in patients with lower-risk transient or persistent minor neurologic events. JAMA Neurol 76(12):1439–1445

    Article  PubMed  PubMed Central  Google Scholar 

  15. Whiteley WN, MacRaild A, Wang Y (2022) Clinical diagnosis and magnetic resonance imaging in patients with transient and minor neurological symptoms: a prospective cohort study. Stroke 53(11):3419–3428

    Article  PubMed  PubMed Central  Google Scholar 

  16. Waters MJ, Cheong E, Jannes J, Kleinig T (2018) Ischaemic stroke may symptomatically manifest as migraine aura. J Clin Neurosci 55:62–64

    Article  PubMed  Google Scholar 

  17. Fisher CM (1968) Migraine accompaniments versus arteriosclerotic ischemia. Trans Am Neurol Assoc 93:211–213

    CAS  PubMed  Google Scholar 

  18. Scutelnic A, Justus L, Branca M et al (2023) Factors associated with migraine aura-like symptoms in acute ischemic stroke. J Neurol 270(7):3637–3641

    Article  PubMed  Google Scholar 

  19. Ali MW, Musami UB, Sa’ad FK, et al (2020) Profile of migraine patients in a developing country: a multicentre study. SN Compr Clin Med 2:1153–1157

    Article  Google Scholar 

  20. Lau YH, Kurien JK, Lau KM et al (2022) Clinical profile of migraine patients: a descriptive study of a single tertiary centre in Malaysia. SN Compr Clin Med 4:22

    Article  Google Scholar 

Download references


This study received research support from the Swiss Heart Foundation (FF21070).

Author information

Authors and Affiliations



Study concept: AS, CJS; data acquisition: AS, MB, HD; data analysis: AS, CJS, HPM; drafting of the manuscript: AS, CJS; writing the subsequent drafts: all authors; critical revision of the article for intellectual content: all authors.

Corresponding author

Correspondence to Adrian Scutelnic.

Ethics declarations

Competing interests

HD, NS, MB, JL, FR: none; AS and SJ report research support from the Swiss Heart Foundation. AK has received research support from the Bangerter-Rhyner Foundation. UF: consulting for Medtronic, Stryker, CSL Behring. Advisory boards for Portola/Alexion (money paid to institution). MA reports personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Covidien, Daiichy Sankyo, Medtronic, Novartis, Pfizer, and Amgen. HPM: Grants from Abbott for the PC and PRIMA trials and from Cerenovus for the ARISE studies. Personal and speaker fees from Cerenovus, Bayer, Servier, Medtronic and Stryker. CJS: consulting, advisory boards, speaker, travel support for/from Novartis, Eli Lilly, TEVA Pharmaceuticals, Allergan, Almirall, Amgen, Lundbeck, MindMed, Grünenthal. Part-time-employee at Zynnon.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised: The Results section of the Abstract has been updated.

Supplementary Information

Additional file 1: Table S1.

Post-hoc power calculations for the comparisons of the C-characteristics. Table S2. Post-hoc power calculation for the number of fulfilled C-characteristics. Table S3. Post-hoc power calculation for the number of symptoms. Table S4. Goodness of fit calculations for adjustment model including sex and age for C-characteristics as outcomes.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scutelnic, A., Drangova, H., Klein, A. et al. Changes of migraine aura with advancing age of patients. J Headache Pain 24, 100 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: